Discussion on purchasing channels of bosutinib/bosutinib

Bosutinib/Bosutinib (Bosutinib) is a targeted drug that is widely used in the treatment of chronic myelogenous leukemia (CML) and leukemia (AP, BP Ph+ CML). As a small molecule tyrosine kinase inhibitor, bosutinib is mainly targeted at patients who are resistant or intolerant to previous treatments. Its mechanism of action is to effectively prevent the proliferation of leukemia cells and promote apoptosis by inhibiting the activity of BCR-ABL tyrosine kinase. This characteristic allows bosutinib to overcome the resistance caused by other tyrosine kinase inhibitors to a certain extent, providing patients with a new treatment option.

Although bosutinib is widely used around the world, its original drug is not yet on the market in China, and therefore cannot be included in the national medical insurance for the time being. For patients who need to use bosutinib, they usually need to purchase it through overseas channels. Currently, the original version of bosutinib on the international market comes from Türkiye, Europe, Switzerland and other regions. In addition, India also produces some generic drugs of bosutinib. Although the ingredients of these generic drugs are basically the same, there may be certain differences in production processes and quality control.

Patients can obtain bosutinib in a variety of ways. For example, some patients will choose to use international drug purchasing platforms. Such websites often provide drug information from different countries, and patients can choose the appropriate version of the drug according to their needs. In addition, there are some specialized drug purchasing companies and individuals who will assist patients to obtain the bosutinib they need from overseas pharmacies or hospitals. When choosing purchase channels, patients should pay special attention to the authenticity of drugs and related legal risks to ensure that the drugs purchased meet safety standards and effectively protect their own rights and interests.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif